Global Esophageal Cancer Market Proliferate Relentlessly; Asserts MRFR Unleashing Industry Forecast Up To 2023 :

Pune, India, January, 2018/MRFR Press Release/- Market Research Future published a Half Cooked research report on “Global Esophageal Cancer Market Research Report - Forecast till 2023”  – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023.

Esophageal is the tube like structure that connects mouth to stomach and help to get foods and liquid. Esophageal cancer develop uncontrolled cancerous cells anywhere along the esophagus. Esophageal cancer consider as a sixth most common cause of cancer deaths around the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and such other factors. The two main sub-types of esophageal cancer are esophageal squamous-cell carcinoma which arises from the epithelial cells and esophageal adenocarcinoma which arises from the glandular cells. According to the American Cancer Society in 2017 the esophageal cancer rate in the United States was about 16,940 cases diagnosed resulting in 15,690 deaths. The disease is also 3 to 4 times more common among men than women.

Global Esophageal Cancer Market – Overview

The global esophageal cancer market is showing the steady growth; mainly owing to increase in patient population. Also, the chances of develop esophageal cancer increases with age and the occurrence of esophageal cancer are much low in children and young adults in comparison to people over 55 year. According to report published by Cancer Research UK, in 2014, it is estimated that around 8,919 incidence of esophageal cancer found in the United Kingdom. These rising number of esophageal cancer create an opportunity for the player to introduce innovative treatment option.

Companies are continuously invent new treatment to capture the global market. Thus players invest more in merger and acquisition activities. In this regards, Leap Therapeutics, Inc. announced the completion of its merger with Macrocure Ltd. This acquisition provide access to Macrocure for Leap Therapeutics' pipeline candidates - DKN-01 and TRX518.These companies are more investing in research and development program to provide the best treatment option, which help them to keep ahead with their competitor.

In 2016, CANbridge Life Sciences has signed an agreement with Boehringer Ingelheim for the manufacture of CAN-017, an ErbB3 (HER3) inhibitory antibody to treat esophageal squamous cell cancer. Increasing in the consumption of smoking, alcohol, leads the incidence of esophageal cancer.

Global Esophageal Cancer Market - Regional Analysis

Amgen Inc. (U.S.), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche (Switzerland), Bristol-Myers Squibb Company (U.S.), Boehringer Ingelheim GmbH (Germany), Bristol-Myers Squibb (U.S.), GlaxoSmithKline Plc. (U.K), Novartis AG (Switzerland), Johnson & Johnson (U.S.), Gilead Sciences, Inc. (U.S.), Merck & Co., Inc. (U.S.) are some of the leading players at the cutting edge of the competition in the market of esophageal cancer, globally.

The market of esophageal cancer is much higher in the Americas region attribute to high rate of tobacco, alcohol, very hot drinks, poor diet, and chewing betel nut. According to report published by American Cancer Society, in 2018, it is estimated that around 17,290 new cases of esophageal cancer diagnosed in Americas which include 13,480 of men and 3,810 of women and around 15,850 will be die. Additionally, In the United States, up to 200,000 people die each year from smoking-related illnesses that leads to incidence of esophageal cancer in this region. The government have more focus towards research and development for introducing the best treatment for their population.

Europe is also consider huge market for esophageal cancer players, owing to present of huge population affected with disease. According to Cancer Research U.K, in 2014, esophageal cancer holds 2 percent of total cancer cases in United Kingdom. Government are more focusing to educate their public in order to minimize the patient’s population by educating them about the side effect of tobacco, alcohol etc.

Asia Pacific region are considering the growing market, owing to presence of huge population suffering with esophageal cancer. Whereas country like India and china are considering fastest growing region due to the high rate of tobacco and alcohol consumption which leads the incidence of esophageal cancer, additionally they are open to adopt new technology, and best treatment option from developed countries in order to improve the quality of life for their citizen. Whereas, the Middle East and Africa have low market due to his incapability of investment, Moreover, developing countries are still focusing on new drugs for the treatment of esophageal cancer, this gap between the developed and developing countries will present significant growth opportunity for the esophageal cancer market players in the coming years.


Browse Full Report @